Microbion for Allergic Rhinoconjunctivitis
Microbion (Lactobacillus plantarum 299) can be used as adjunct therapy for allergic rhinoconjunctivitis in adults, but it should not replace standard first-line treatments. The recommended regimen is 2 capsules by mouth once daily 1.
Treatment Framework
Primary Treatment Remains Standard Therapy
The established guidelines are clear about first-line management. For adults with allergic rhinoconjunctivitis affecting quality of life, intranasal corticosteroids are the primary recommendation 2. These are the most effective medication class for controlling all four major symptoms: sneezing, itching, rhinorrhea, and nasal congestion 3. Second-generation oral antihistamines are strongly recommended for patients whose primary complaints are sneezing and itching 2.
For the ocular component specifically, intranasal corticosteroids, oral antihistamines, intranasal antihistamines, and oral leukotriene receptor antagonists all provide relief of associated eye symptoms 3.
Role of Probiotics as Adjunct
The evidence for probiotics in allergic rhinoconjunctivitis shows modest but consistent benefits:
Symptom improvement: Recent high-quality meta-analyses demonstrate that probiotic supplementation significantly reduces nasal symptoms including rhinorrhea, nasal itching, nasal congestion, sneezing, and ocular itching 4, 5, 6. The 2026 umbrella review found weighted mean differences showing improvement in nasal symptoms (WMD: -1.97) and quality of life scores 6.
Clinical significance: The effect sizes are small but clinically meaningful. One meta-analysis specifically noted that the standardized mean difference of -0.34 for individual nasal symptoms exceeded the minimal important clinical difference threshold of 0.3 7.
Quality of life: Multiple studies confirm significant improvements in rhinoconjunctivitis quality of life questionnaire (RQLQ) scores, with reductions in both global and nasal-specific domains 4, 5, 6.
Specific Considerations for Lactobacillus plantarum
While Microbion contains Lactobacillus plantarum 299, the strongest evidence exists for Lactobacillus paracasei strains (particularly LP-33), where all five studies in one meta-analysis showed clinically significant improvements 7. However, Lactobacillus species generally have demonstrated anti-allergic effects through immunomodulation 8.
The mechanism appears to involve restoring Th1/Th2 balance, with studies showing increased Th1/Th2 ratios after probiotic supplementation 5, 6. However, effects on IgE levels are inconsistent, with some studies showing reductions in total IgE but not antigen-specific IgE 5, 6.
Practical Algorithm
Step 1: Initiate standard therapy
- Start intranasal corticosteroid (e.g., fluticasone, mometasone) for moderate-to-severe symptoms
- Add second-generation oral antihistamine (e.g., cetirizine, loratadine) if sneezing and itching predominate
Step 2: Assess response after 2-4 weeks
- If inadequate response, optimize intranasal corticosteroid dosing and adherence
- Consider adding intranasal antihistamine for combination therapy 2, 9
Step 3: Consider probiotic adjunct
- Add Microbion 2 capsules daily if symptoms persist despite optimized pharmacotherapy
- Continue for minimum 8 weeks to assess benefit 10, 11
- Expect gradual improvement rather than immediate relief
Step 4: Evaluate for immunotherapy
- If inadequate response to pharmacologic therapy with or without probiotics, refer for allergen immunotherapy (sublingual or subcutaneous) 2
Important Caveats
Contraindications: Microbion is contraindicated in patients with known hypersensitivity to any ingredients 1. Use caution in immunocompromised patients, though this is not explicitly stated in the label.
Storage requirements: Critical to maintain efficacy—store unopened bottles at room temperature (68-77°F), but refrigerate after opening at 35-46°F; do not freeze 1.
Evidence limitations: The probiotic evidence shows high heterogeneity across studies 4, 5, 6. Different strains have different effects, and results cannot be extrapolated between species or even strains within the same species 12. The 2026 umbrella review noted that routine clinical recommendation is not supported by high-certainty evidence due to pooling of diverse strains 6.
Safety profile: Probiotics demonstrate favorable safety with minimal side effects reported across trials 4, 5, 11. No serious adverse events were attributed to probiotic use in the included studies.
Not a replacement: Guidelines do not recommend probiotics as primary therapy. The 2015 AAO-HNS guideline states "no recommendation regarding the use of herbal therapy" (which would include dietary supplements like probiotics) 2, reflecting insufficient evidence at that time to make formal recommendations.
The most recent 2026 evidence suggests probiotics provide approximately 33% greater symptom reduction compared to placebo 10, which is meaningful but substantially less than the 50-70% improvement typically seen with intranasal corticosteroids.